135 related articles for article (PubMed ID: 9070502)
1. Differential activity of Cremophor EL and paclitaxel in patients' tumor cells and human carcinoma cell lines in vitro.
Csóka K; Dhar S; Fridborg H; Larsson R; Nygren P
Cancer; 1997 Mar; 79(6):1225-33. PubMed ID: 9070502
[TBL] [Abstract][Full Text] [Related]
2. Cell line and schedule-dependent cytotoxicity of paclitaxel (Taxol): role of the solvent Cremophor EL/ethanol.
Cordes N; Plasswilm L
Anticancer Res; 1998; 18(3A):1851-7. PubMed ID: 9673415
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxic activity of a new paclitaxel formulation, Pacliex, in vitro and in vivo.
Hassan S; Dhar S; Sandström M; Arsenau D; Budnikova M; Lokot I; Lobanov N; Karlsson MO; Larsson R; Lindhagen E
Cancer Chemother Pharmacol; 2005 Jan; 55(1):47-54. PubMed ID: 15565443
[TBL] [Abstract][Full Text] [Related]
4. The cytotoxic activity of Taxol in primary cultures of tumour cells from patients is partly mediated by Cremophor EL.
Nygren P; Csoka K; Jonsson B; Fridborg H; Bergh J; Hagberg H; Glimelius B; Brodin O; Tholander B; Kreuger A
Br J Cancer; 1995 Mar; 71(3):478-81. PubMed ID: 7880727
[TBL] [Abstract][Full Text] [Related]
5. Multidrug resistance phenotype and paclitaxel (Taxol) sensitivity in human renal carcinoma cell lines of different histologic types.
Reinecke P; Schmitz M; Schneider EM; Gabbert HE; Gerharz CD
Cancer Invest; 2000; 18(7):614-25. PubMed ID: 11036469
[TBL] [Abstract][Full Text] [Related]
6. Paclitaxel-induced cytotoxicity--the effects of cremophor EL (castor oil) on two human breast cancer cell lines with acquired multidrug resistant phenotype and induced expression of the permeability glycoprotein.
Fjällskog ML; Frii L; Bergh J
Eur J Cancer; 1994; 30A(5):687-90. PubMed ID: 7915908
[TBL] [Abstract][Full Text] [Related]
7. Interaction of paclitaxel (Taxol) and irradiation. In-vitro differences between tumor and fibroblastic cells.
Cordes N; Plasswilm L; Sauer R
Strahlenther Onkol; 1999 Apr; 175(4):175-81. PubMed ID: 10230460
[TBL] [Abstract][Full Text] [Related]
8. Effects of paclitaxel with or without cremophor EL on cellular clonogenic survival and apoptosis.
Engblom P; Pulkkinen JO; Rantanen V; Hirvonen H; Kulmala J; Grènman R; Grènman S
Eur J Cancer; 1999 Feb; 35(2):284-8. PubMed ID: 10448272
[TBL] [Abstract][Full Text] [Related]
9. Measurement of cremophor EL following taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype.
Webster L; Linsenmeyer M; Millward M; Morton C; Bishop J; Woodcock D
J Natl Cancer Inst; 1993 Oct; 85(20):1685-90. PubMed ID: 8105099
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxicity of fractionated paclitaxel (Taxol) administration in vitro.
Plasswilm L; Cordes N; Fietkau R; Sauer R
Strahlenther Onkol; 1998 Jan; 174(1):37-42. PubMed ID: 9463563
[TBL] [Abstract][Full Text] [Related]
11. Antiproliferative effects of paclitaxel (Taxol) on human renal clear cell carcinomas in vitro.
Reinecke P; Corvin J; Gabbert HE; Gerharz CD
Eur J Cancer; 1997 Jun; 33(7):1122-9. PubMed ID: 9376193
[TBL] [Abstract][Full Text] [Related]
12. Effect of paclitaxel and Cremophor EL on mast cell histamine secretion and their interaction with adriamycin.
Decorti G; Bartoli Klugmann F; Candussio L; Baldini L
Anticancer Res; 1996; 16(1):317-20. PubMed ID: 8615628
[TBL] [Abstract][Full Text] [Related]
13. Proliferation, migration and invasion of human glioma cells exposed to paclitaxel (Taxol) in vitro.
Terzis AJ; Thorsen F; Heese O; Visted T; Bjerkvig R; Dahl O; Arnold H; Gundersen G
Br J Cancer; 1997; 75(12):1744-52. PubMed ID: 9192976
[TBL] [Abstract][Full Text] [Related]
14. Comparative in vitro properties and clinical pharmacokinetics of Paclitaxel following the administration of taxol(r) and paxene(r).
Scripture CD; Szebeni J; Loos WJ; Figg WD; Sparreboom A
Cancer Biol Ther; 2005 May; 4(5):555-60. PubMed ID: 15917657
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation.
Danhier F; Lecouturier N; Vroman B; Jérôme C; Marchand-Brynaert J; Feron O; Préat V
J Control Release; 2009 Jan; 133(1):11-7. PubMed ID: 18950666
[TBL] [Abstract][Full Text] [Related]
16. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL.
Sparreboom A; van Tellingen O; Nooijen WJ; Beijnen JH
Cancer Res; 1996 May; 56(9):2112-5. PubMed ID: 8616858
[TBL] [Abstract][Full Text] [Related]
17. [Study for modifying activity of solvents on antitumor activity of paclitaxel].
Fujimoto S
Gan To Kagaku Ryoho; 1994 Apr; 21(5):665-70. PubMed ID: 7908793
[TBL] [Abstract][Full Text] [Related]
18. Effect of paclitaxel (Taxol) on CA 125 expression and release by ovarian cancer cell lines.
Bonfrer JM; Linders TC; Hageman PC; Hilkens JG; Korse CM; Molthoff CF
Tumour Biol; 1997; 18(4):232-40. PubMed ID: 9218008
[TBL] [Abstract][Full Text] [Related]
19. Cremophor-EL enhances taxol efficacy in a multi-drug resistant C1300 neuroblastoma cell line.
Chervinsky DS; Brecher ML; Hoelcle MJ
Anticancer Res; 1993; 13(1):93-6. PubMed ID: 8097392
[TBL] [Abstract][Full Text] [Related]
20. The influence of Cremophor EL on the cell cycle effects of paclitaxel (Taxol) in human tumor cell lines.
Liebmann J; Cook JA; Lipschultz C; Teague D; Fisher J; Mitchell JB
Cancer Chemother Pharmacol; 1994; 33(4):331-9. PubMed ID: 7904231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
